Hansoh Pharmaceutical Group Company Limited
3692
Ранг среди акций
#904
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Цена акции
$4.40
Рыночная капитализация
$26.66B
Изменение (1 день)
0.00%
Изменение (1 год)
-4.79%
Страна
CN
Торговля Hansoh Pharmaceutical Group Company Limited (3692)
Категория
Healthcare
Прибыль Hansoh Pharmaceutical Group Company Limited (3692)
Прибыль на Jun 2026 TTM: $1.14B
Согласно последним финансовым отчетам Hansoh Pharmaceutical Group Company Limited, текущая прибыль компании составляет $1.14B. В 2023 году компания получила прибыль $532.05M, больше, чем прибыли за 2022, которая составила $427.44M. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Hansoh Pharmaceutical Group Company Limited с 2016 по 2026
Прибыль в конце каждого года
| Год | Прибыль | Изменить |
|---|---|---|
| 2026 (TTM) | $1.14B | 63.74% |
| 2024 | $696.69M | 30.94% |
| 2023 | $532.05M | 24.47% |
| 2022 | $427.44M | -17.68% |
| 2021 | $519.22M | 9.48% |
| 2020 | $474.28M | 10.05% |
| 2019 | $430.96M | 28.37% |
| 2018 | $335.73M | 13.01% |
| 2017 | $297.07M | 14.31% |
| 2016 | $259.87M | 0.00% |
Прибыль схожих компаний или конкурентов
| Компания | Прибыль | Разница в прибыли | Страна |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 54.69% |
IN
|
